Clinical Trial Update: Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine [Phase 3]

View source ↗

Summary

Phase 3 safety and immunogenicity study evaluating a booster dose of GlaxoSmithKline's 10-valent pneumococcal conjugate vaccine; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections
• Streptococcal Infections

Drugs mentioned

• Pneumococcal Conjugate Vaccine 10-valent (Pneumococcal conjugate vaccine, 10-valent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Streptococcal | Phase 3 | Status: COMPLETED